Azitra, Inc. (AZTR) Stock Price & Analysis
Azitra, Inc. (AZTR) rose 3.94% to USD 0.21 as of June 10, 2026 at 02:34 UTC, according to Nexqual real-time market data.
AZTR last closed at USD 0.2; the session ranged USD 0.2–0.21 on volume of 361,999 shares. Market capitalization is $3.44M, with a 52-week range of USD 0.1–2.4 (ASE). Source: Nexqual, June 10, 2026 at 02:34 UTC.
Key Statistics (as of June 10, 2026 at 02:34 UTC)
| Price | USD 0.21 |
|---|---|
| Change | ▲ 3.94% (up) |
| Previous Close | USD 0.2 |
| Open | USD 0.2 |
| Day Range | USD 0.2 – 0.21 |
| 52-Week Range | USD 0.1 – 2.4 |
| Volume | 361,999 shares |
| Market Cap | $3.44M |
| Exchange | ASE |
Technical Analysis (AZTR)
Nexqual's technical model rates AZTR "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.59 (neutral) |
| vs SMA50 | Below (USD 0.22) |
| MACD | -0 (negative) |
Analyst Ratings (AZTR)
Wall Street analysts rate AZTR "None" based on 2 analysts, with a mean price target of USD 0.78 (range USD 0.55–1), per Nexqual as of June 10, 2026 at 02:34 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 0.78 |
| High Target | USD 1 |
| Low Target | USD 0.55 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (AZTR)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.25 vs est -0.04 ▼ miss |
| 2025-12-31 | USD -1.17 vs est -0.33 ▼ miss |
| 2025-09-30 | USD -0.67 vs est -0.78 ▲ beat |
| 2025-06-30 | USD -1.2 vs est -1.4 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Financials & Fundamentals (AZTR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -158.71% |
| Debt / Equity | 3.28 |
| Current Ratio | 6.94 |
| Total Cash | $10.05M |
| Total Debt | $343,330 |
| Free Cash Flow | $-6.67M |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Financial Health Score (AZTR)
Nexqual rates Azitra, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:34 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -159%, ROA -81.8% |
Ownership (AZTR)
| Insider Ownership | +3.38% |
|---|---|
| Institutional Ownership | +3.33% |
| Shares Outstanding | 16.19M |
| Float | 16.18M |
| Short % of Float | +0.58% |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Leadership (AZTR)
Azitra, Inc. is led by Francisco D. Salva (age 54), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:34 UTC.
| President, CEO & Director | Francisco D. Salva (age 54) |
|---|---|
| Co-Founder, COO, Secretary & Director | Travis M. Whitfill M.P.H. (age 35) |
| CFO & Treasurer | Norman Staskey (age 55) |
Major Backers & Investors (AZTR)
Notable institutional backers of Azitra, Inc. include Fidelity, UBS Group AG, Stonex Group Inc., according to Nexqual as of June 10, 2026 at 02:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.89% |
| UBS Group AG | 0.19% |
| Stonex Group Inc. | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 2.9% |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
From Azitra, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- In preclinical studies, we have shown that S. epidermidis homes to layers below the stratum corneum and delivers proteins into the deeper epidermis. 5 To expand upon our recombinant protein construction capabilities, we have acquired an exclusive license to proprietary technology that disguises our genetically engineered DNA sequences to enable the production of proteins in previously intractable bacterial species.
- Since our formation, we have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics.
- We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics.
- To address this challenge, we have developed a proprietary process capable of facilitating protein delivery in a manner that bypasses the normally impenetrable stratum corneum.
Partnerships
- Through our collaboration with Chemia Biosciences, we are able to use their proprietary genomic and peptidomic artificial intelligence and machine learning system, NRPMiner, to develop and confirm natural product predictions of the proteins, peptides and small molecules that are generated by our proprietary bacterial library.
- Our collaboration with the Carnegie Mellon team takes advantage of the power of whole genome sequencing.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LRHC | La Rosa Holdings Corp. | USD 1.05 | ▲ 0% |
| ATPC | Agape ATP Corporation | USD 3.12 | ▲ 4.7% |
| NIVF | NewGenIvf Group Limited | USD 0.49 | ▼ 22.88% |
| VTAK | Catheter Precision, Inc. | USD 1 | ▼ 3.2% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:34 UTC. This page is informational and not investment advice.